Hello everyone! My name is Kramer Kaplan, and I am a current graduate student working on fish genetics. My advisor and I are learning how to go through the process of 2D sequencing to obtain the entire mitochondrial genome of two species of freshwater stingrays. I wanted to submit a post here with several questions that I had. We have been using a PCR Barcoding Kit (EXP-PBC001) that has the twelve barcodes and barcode adapter mixes (BCA). I was wondering when you use that adapter mix because it does not say anything about that in the protocol. I'm following the "PCR barcoding amplicon sequencing for the MinION device using SQK-NSK007." As I have been following this protocol, the issue I have been seeing is my concentrations of DNA keep getting less and less until I have less than 20ng/ul. Before prepping the MinION, I am supposed to have around 150ng/ul of material. My first found PCR product showed about 10kB on a gel, and the concentrations were high enough, so I truly do not know what the issue is. If anyone could shed some light on these issues or offer any advice, that would be greatly appreciated!
-
-
Hi! You can ligate the BCA to any DNA and then do a barcoded PCR, e.g if you want to use genomic DNA or have amplicons without the ONT pcr-priming tail. We also tend to get lower than recommended yield of DNA after the final streptavidin bead purification, but I think 20 ng/ul is still high. If you only get 20 ng in total then something is likely wrong, perhaps adaptors are too old or your starting concentration was off.
-
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...07-31-2026, 11:01 AM -
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM
Comment